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Paola Bozzatello et al. [1] have done a comprehensive qualitative review of the potential use
of long-chain polyunsaturated fatty acids in the prevention and treatment of mental disorders.
The number of placebo-controlled trials across a range of mental disorders has surged substantially
over the last two decades; however, only very few well-designed large scale trials have been performed.
Therefore, even in conditions like schizophrenia, depression or attention deficit and hyperactivity
disorders (ADHD) where most omega-3 fatty acid RCTs have been performed, no final conclusions
regarding the use of omega-3 fatty acids can be drawn yet. One of the key problems of systematic
reviews investigating the use of omega-3 fatty acids in mental disorders is that they have integrated
quite diverse phenotypic groups, e.g., the use of omega-3 fatty acids in controlled treatment trials that
also assessed depressive symptoms included the following different conditions:
Primary diagnosis of adult major depressive disorders (MDD) [2–16]
Depressive episodes in bipolar affective disorders [17–23]
Depression during or post pregnancy (postpartum depression) [24–26]
Depression in non-MDD mood disorders (e.g., premenstrual syndrome, dysthymia) [27–32]
Depression in other psychiatric conditions (e.g., borderline PD, self-harm, OCD) [33–37]
Depression in established schizophrenia [2,38]
Depression in Alzheimer’s dementia/mild cognitive impairment [13,39,40]
Depression in Parkinson disease [41]
Depression in medical conditions (cerebro-vascular and metabolic diseases or cancer) [42–46]
Depressive symptoms in healthy individuals [47–52]
Several meta-analytic reviews have tried to integrate the above-mentioned very heterogeneous
controlled treatment trials investigating the effects of omega-3 fatty acids on mood symptoms [53–59].
Most meta-analysis including RCTs investigating depressive syndromes confirmed a statistical
significant effect in favour of omega-3 fatty acids with minimal to moderate effect sizes depending
on the selection of studies (except of one meta-analysis [57]). Effect sizes in favour of omega-3 fatty
acids [60] are larger if RCTs are selected based on (1) a EPA/DHA ratio >60% of the overall omega-3
fatty acid content [54,56] and (2) only RCTs with a primary diagnosis of MDD are included [54,59].
To our knowledge, only one pilot RCT (n = 20) in children with a mean age of 10 was performed [61].
Martins et al.’s [54] meta-analysis including RCTs with primary and secondary MDD found a significant
overall SMD = ´0.291 in favour of omega-3 fatty acids, but also detected a marked study heterogeneity
and evidence for publication bias. A more recent meta-analysis by Sublette et al. [56] only including
primary MDD RCTs dichotomized according to a EPA/DHA ratio >60% of the overall omega-3 fatty
acids content found a moderate effect size (SMD = 0.558) with negligible contribution of random
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effects or heteroscedasticity. Bloch and Hannestadl’s meta-analysis [57] including studies with
mildly depressed individuals not meeting criteria for clinical depression could not replicate previous
meta-analyses; however, a sub-analysis restricted to moderate to marked depression confirmed an
SMD of 0.42 in favour of omega-3 fatty acid treatment. It is likely that a single study by Rogers et al. [27]
investigating the effects of omega-3 fatty acids on mild depressive symptoms in a large non-clinical
population was responsible for the negative overall outcome as the Rogers study accounted for 31.7%
of the overall weight in this particular meta-analysis [62]. Grosso et al. [59] found a SMD = 0.56 for
primary MDD, an SMD = 0.22 for non-primary MDD, and an overall SMD = 0.38 in favour of omega-3
fatty acid compared to placebo treatment. The above mentioned meta-analyses suggest that mainly
the use of EPA rather than DHA rich formulations are responsible for the clinical efficacy of omega-3
fatty acids. Unexpected is the finding that the use of purified or DHA-enriched oils is not successful in
treating depression, postnatal depression or OCD [4,63,64]. This finding is in contrast to the greater
face validity of DHA, which is the major brain omega-3 fatty acids and which is lower in brain tissue
of depressed suicide victims [65].
Two RCTs encompassing a large proportion of patients with refractory depression highlight the
potential use of EPA-enriched omega-3 fatty acids as an augmentation treatment of antidepressants
(potentially via an increase in membrane fluidity) [2,3]. Two RCTs in populations without a primary
MDD provide evidence of an association between inflammation and omega-3 fatty acids response:
(1) A placebo-controlled trial investigating the positive effects of omega-3 fatty acids on depressive
symptoms and chronic inflammation in haemodialysis patients [66]; and (2) a study [67] that found
a preventive effect of EPA against the development of depressive symptoms in IFN-alpha-treated
hepatitis C virus carriers (associated with a very high risk of drug-induced depressive symptoms).
The latter two studies suggest that omega-3 fatty acids rich in EPA may modulate its antidepressant
properties via immune-modulatory strategies, which is of interest in the light of more recent models of
the underlying pathophysiology of a range of mental disorders [68].
A whole range of RCTs have also been performed in schizophrenia and related disorders. A study
in first episode psychosis adolescents demonstrates that omega-3 fatty acids augmentation treatment
of antipsychotic medication may result in a better tolerability (less EPS, less sexual side effects) and
faster response to antipsychotic medication; however, at the end of the three month treatment period,
there was no difference in treatment effects on all primary outcome measures between active and
placebo [69]. The final outcome of this study is in line with a meta-analysis of Dr. Fusar-Poli and the
author of this commentary coming to the conclusion that omega-3 fatty acids in established (but not
prodromal) schizophrenia have no or only minor additional efficacy compared to currently available
treatments (also not on depressive symptoms in schizophrenia) [70], but may have some beneficial
effects in tertiary prevention.
The use of omega-3 fatty acids in primary (indicated) prevention of mental disorders in general
may be a separate important area of omega-3 fatty acid research that goes beyond the schizophrenia
prodrome, and is an avenue yet to be further explored. A pilot RCT in 81 adolescents at ultra-high risk
(UHR) for developing a psychotic disorder (mean age 16.4) compared 1.2 g of an EPA-enriched omega-3
fatty acids oil as a sole agent with a placebo oil in a double blind fashion [71]. A total of 27.5% in the
placebo group progressed towards a first psychotic episode compared to only 4.9% in the omega-3
fatty acids group. A recent multinational multicentre study (the NEURAPRO study [72]) including
over 300 UHR adolescents tried to replicate this promising pilot study. However, the key problem of
the replication study is that the overall transition rate of the study after one year was as low as 10.5%
and the compliance rate of 43% was very poor so that a reasonable conclusion at this stage of data
analysis is not really appropriate [73]. Another multinational multi-centre omega-3 RCT in prodromal
schizophrenia will start in the near future (the PURPOSE trial). Bozzatello et al. [1] discussed the latter
studies in the schizophrenia section. However, as only 10% to 20% of URH adolescents will progress
to a first psychotic episode within one year and only about half these first episode cases actually
meet criteria for core schizophrenia, it is probably not correct to discuss URH studies within the
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schizophrenia section. It may be much more appropriate to investigate neuroprotective interventions
like omega-3 fatty acids not solely within a schizophrenia concept, but much more in the light of
brain developmental factors and biological relevant markers, such as the inflammatory markers, the
omega-3 index or markers of neuronal damage (e.g., TNF-beta).
The above mentioned small pilot omega-3 RCT in prepubertal children with childhood-onset
depression shows a very large effect size (SMD = 1.2) [61]. Also the pilot study in UHR adolescents for
psychosis [71] with a mean age of 16.1 showed large effect sizes. Furthermore, most omega-3 fatty acids
RCTs in children were done in ADHD and show a beneficial effect. Bloch et al.’s meta-analysis [74]
including 699 ADHD children of ten RCTs between 7 and 12 years found a beneficial effect in favour
of omega-3 fatty acids with a SMD of 0.31 with no evidence of publication bias and a significant dose
dependency; RCTs using a daily dose of 500 to 750mg EPA were the most effective ones [75]. Even so,
the effect size of stimulant treatment with methylphenidate, dexamphetamines or atomotexine is still
two to four times stronger compared to omega-3 fatty acids alone, the positive findings of omega-3
fatty acid studies in children is suggestive that in particular the developing brain may benefit from
omega-3 fatty acids. Future research has to address the question if subgroups of children with mental
disorders may benefit more from benign interventions like omega-3 fatty acids compared to adults
with established (end stage) mental disorders.
For all other mental disorders and associated conditions only limited evidence exists to promote
or refute the use of Omega-3 fatty acids in daily clinical care. As outlined by Bozzatello et al. [1],
there is some evidence that omega-3 fatty acids augmentation may have some beneficial effects in
bipolar affective disorders [17], in particular against depressive symptoms [19,76]. Furthermore,
EPA-enriched omega-3 fatty acids may also attenuate impulsivity in patients with Borderline
Personality Disorder [35,77] and incarcerated young males [78]. The latter findings may be of particular
importance for male pediatric MDD individuals that sometimes present with impulsive and aggressive
behaviour rather than sadness [25]. A recently published trial in adolescents with conduct disorders
highlights the importance to implement long study durations (e.g., one year) to be able to demonstrate
potential positive effects of omega-3 fatty acids on difficult to treat behavioural traits [79]. Worth
mentioning is a recent RCT in premenstrual syndrome (PMS) showing some beneficial effects on
depression, nervousness, anxiety, lack of concentration and a reduction of somatic symptoms such
as bloating, headaches and breast tenderness [32]. These studies need replication, but point towards
important phenotypic features that may benefit from omega-3 fatty acids, such as impulsivity. We may
consider more complex trial designs to address the questions if omega-3 fatty acids may be of
importance across a whole range of mental disorders, in particular in childhood and adolescents
and for certain phenotypic features.
The underlying mechanisms of the potential preventive and therapeutic actions of omega-3
fatty acids against mental disorder are still unclear. Preclinical and clinical data point towards
several mechanisms most likely acting in concert [80]. Some of them might be more responsible
for short-term, other for postulated long-term effects of omega-3 fatty acids. There is some preclinical
evidence that Omega-3 fatty acids may modulate the HPA-axis that is suggested to play a role
in a range of mental disorders [81]. Omega-3 fatty acids have shown to attenuate stress-related
changes in animal models with depressive features [82–85] as well as in humans [86–88]. Furthermore,
Omega-3 fatty acids may influence myelination and synaptic pruning, important processes for normal
pubertal brain development. The regulation of PUFA metabolism is crucial for both processes [89,90].
Of particular interest is a preclinical study investigating cognition and behaviour across different
developmental stages. Omega-3 fatty acids deficient diets across consecutive generations produced
a modality-selective and task-dependent impairment in cognitive and motivated behaviour in
adolescence distinct from the deficits observed in adults [91,92]. Omega-3 fatty acids attenuate such
depression-like animal behaviours during critical periods of brain development [93]. Furthermore, the
FADS haplotype determining LC-PUFAs availability and concentrations in white matter (WM) showed
age-related WM differences in humans (significant age ˆ genotype interactions, p(corrected) < 0.05).
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PUFA metabolism is therefore likely to play a role in disorders of neurodevelopmental origin [94].
Animal models with structural hippocampal alterations with depression-like and anxiety-like
behaviours [95,96] provide evidence that omega-3 fatty acids have a preventive and neurotrophic
effect against hippocampal changes [97,98]. Omega-3 fatty acids enhance hippocampal cell viability
and are able to protect hippocampal cells from stress-related damage [99]. Monoaminergic transmitter
systems are proposed to be involved in the pathogenesis of many mental disorders. Animal
experiments of omega-3 fatty acids deprived rats provide evidence for an increase in serotonin 2
(5-HT2) and a decrease in dopamine 2 (D2) receptor density in the frontal cortex, as well as an
increased serotonin turnover in the prefrontal cortex and decreased midbrain tryptophan hydroxylase-2
expression [100–106]. In humans, omege-3 intake is associated with an increase in cerebrospinal
fluid 5-HIAA release [107,108]. Several lines of evidence support that Omega-3 fatty acids have
immune-modulatory, anti-inflammatory and pro-resolving properties [109], e.g., via the modulation of
pro-inflammatory omega-6, the promotion of proresolvins, neuroprotectins and anti-inflammatory
mediators [110–112]. Omega-3 fatty acids seem to induce protective in vivo brain mechanisms against
oxidative stress. Ethyl-EPA supplementation is associated with a marked increase of glutathione,
a strong intracellular antioxidant using proton magnetic resonance spectroscopy in patients with
a first-episode psychosis [113]. Another group found similar effects in older patients at risk for
depression [114]. Some evidence regarding the measurement of glutathione in peripheral blood is also
suggestive that omega-3 fatty acids may support the antioxidative defence system in individuals at
ultra-high risk for psychosis [115]. Finally, a decrease in membrane fluidity can affect the rotation and
diffusion of proteins and other bio-molecules within the membrane, thereby affecting the functions of
these molecules and processes. An increase in membrane fluidity results in a more flexible membrane
and facilitates transmission (e.g., in the retina) [116]. In vivo imaging techniques such as diffusion
tensor imaging could demonstrate that omega-3 fatty acids are closely linked to PUFA metabolism [94].
The effect of omega-3 fatty acids on membrane structure [117] may contribute to its clinical effects,
in particular in augmentation studies. T2-relaxation time normalizes under the influence omega-3
fatty acids potentially being a signifier of normalization in membrane structure [118]. Future studies
should therefore address if particular markers, such as low baseline levels of omega-3 fatty acids,
increased inflammatory mediators, markers of intact myelination (e.g., measured with DTI), or a
functional glia-neuronal interface (e.g., measured with MRS) may serve as predictors of omega-3
fatty acid response, in particular in children and adolescents in the early course of disorders [119].
Bozzatello et al.’s [1] qualitative and comprehensive review is a contribution to this endeavour and
highly recommended to interested readers.
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